Deciphera's Ripretinib Cuts GIST Death Risk By 64%; US Filing On Track For Early 2020

 
• By Leah Samuel
  
Digital illustration of Cancer cell in colour background
Deciphera encouraged by overall survival data
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D